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Hereditary hemorrhagic telangiectasia (HHT) is a genetically heterogeneous disorder,
involving mutations in two predominant genes known as Endoglin (ENG; HHT1) and
activin receptor-like kinase 1 (ACVRL1/ALK1; HHT2), as well as in some less frequent
genes, such as MADH4/SMAD4 (JP-HHT) or BMP9/GDF2 (HHT5). The diagnosis of
HHT patients currently remains at the clinical level, according to the “Curaçao criteria,”
whereas the molecular diagnosis is used to confirm or rule out suspected HHT cases,
especially when a well characterized index case is present in the family or in an
isolated population. Unfortunately, many suspected patients do not present a clear HHT
diagnosis or do not show pathogenic mutations in HHT genes, prompting the need
to investigate additional biomarkers of the disease. Here, several HHT biomarkers and
novel methodological approaches developed during the last years will be reviewed. On
one hand, products detected in plasma or serum samples: soluble proteins (vascular
endothelial growth factor, transforming growth factor b1, soluble endoglin, angiopoietin-2)
andmicroRNA variants (miR-27a, miR-205, miR-210). On the other hand, differential HHT
gene expression fingerprinting, next generation sequencing of a panel of genes involved
in HHT, and infrared spectroscopy combined with artificial neural network patterns will
also be reviewed. All these biomarkers might help to improve and refine HHT diagnosis
by distinguishing from the non-HHT population.
Keywords: biomarkers, HHT, endoglin, ALK1, miRNA, TGF-b, VEGF, Ang-2
Introduction
Hereditary hemorrhagic telangiectasia (HHT; OMIM 187300), or Rendu–Osler–Weber syndrome,
is an inherited autosomal dominant disease affecting 1 in 5,000 individuals as assessed in several
human populations (Shovlin, 2010). The disease is characterized by abnormal vascular structures,
which lead to epistaxis, telangiectases, and anemia as well as visceral arteriovenous malformations
(AVMs) in the lung, brain, and liver. These may contribute to serious health outcomes, such as
strokes, brain abscesses, and hemorrhages (Shovlin, 2010; McDonald et al., 2011).
HHT is a genetically heterogeneous disorder. The first genes identified as mutated in HHT
patients, were Endoglin (ENG), located on chromosome 9q33-34, causing HHT1 (Fernández-Ruiz
et al., 1993; McAllister et al., 1994) and ACVRL1/ALK1 (activin receptor-like kinase 1), that causes
HHT2 (Johnson et al., 1995, 1996). Over 80–85% of the HHT patients present mutations in either
ENG or ACVRL1 genes, while unidentified mutations in additional loci account for the remaining
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FIGURE 1 | Curaçao clinical criteria in HHT. (A) Multiple telangiectases at
characteristic sites, such as oral cavity, ears, and fingers. (B) Visceral lesions
(AVMs) in the lungs, brain, liver or spinal cord, and gastrointestinal bleeding.
(C) Epistaxis (spontaneous, recurrent nosebleeds). (D) An example of a family
history of HHT; a genetic family tree with affected members in red and
non-affected members in blue is shown.
cases. These loci include the HHT3 locus on chromosome 5 or
the HHT4 locus on chromosome 7, whose genes remain uniden-
tified (Cole et al., 2005; Bayrak-Toydemir et al., 2006), along with
mutations in the MADH4/SMAD4 gene causing familial juve-
nile polyposis associated with HHT (Gallione et al., 2004). More
recently, mutations in BMP9/GDF2were described as the cause of
an HHT-like syndrome (Wooderchak-Donahue et al., 2013).
The diagnosis of HHT currently remains at the clinical level.
The consensus clinical criteria, known as “Curaçao criteria,”
are epistaxis (spontaneous, recurrent nosebleeds); telangiectases
(multiple at characteristic sites, such as the lips, oral cavity, fingers,
and nose); visceral lesions (AVMs in the lung, brain, liver, or spinal
cord), gastrointestinal bleeding, and a family history (Faughnan
et al., 2011; Figure 1). Curaçao criteria are particularly helpful in
identifying affected from non-affected adults. However, special
attention must be paid to the risk of not diagnosing HHT in
asymptomatic children and young adults. In these cases, not all
of the typical symptoms may be present. In general, most patients
show a full penetrance of the disease around the age of 40 (Shovlin,
2010; Faughnan et al., 2011).
The genetic testing for HHT genes is the choice option in
children and teenagers, especially if the familymutation is known.
In these cases, the genetic results should be definite for either the
positive diagnosis or exclusion. Current genetic determinations
imply the sequencing of at least two HHT genes. This process
is time-consuming, expensive and in 10–15% of the cases, the
mutation is not identified. Therefore, it would be desirable to have
alternative tools facilitating diagnosis. They should ideally allow
earlier, faster, cheaper, and easier HHT diagnosis.
The use of biomarkers in basic and clinical research, as well
as in clinical practice, has become a commonplace in diagno-
sis, prognosis, and in primary endpoints of clinical trials and
preclinical research studies (Vasan, 2006). The term biomarker
refers to a broad subcategory of medical signs which can be
measured accurately and reproducibly. In 1998, theNational Insti-
tutes of Health (NIH) Biomarkers Definitions Working Group
(2001) defined a biomarker as “a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to
a therapeutic intervention.” Over the last two decades, a large
number of studies have searched for different potential biomark-
ers in HHT. Different ways have been developed in the past
years to improve and facilitate the HHT molecular diagnosis.
On one hand, advances in sequencing procedures have allowed
quicker and more precise sequencing of several genes simul-
taneously. In this context, the recent design of new platforms
for the capture and sequencing of a panel of genes involved in
HHT and related diseases may change the sequencing approach.
On the other hand, emerging non-sequencing methods based
on soluble plasma markers, microRNAs (miRNAs; miRs), or
differential physical patterns distinguishing HHT patients from
the non-HHT population have been described. The pathogenic
haploinsufficiency of the HHT gene products yields a deregulated
genetic expression pattern in the cells most targeted in HHT, the
endothelial cells (Fernandez-L et al., 2007a). As a result, an altered
pattern of protein expression levels, including soluble products,
could be detected in plasma using standard blood tests. In this
same line, the detection of miRNAs related to HHT biology
is also a useful tool which emerges to complete the diagnostic
field.
Direct Diagnostic Methods Based on Genetic
Analysis: Sanger and Next Generation
Sequencing
The classical Sanger sequencing analysis of genes, including genes
found as the main cause for HHT, ENG and ACVRL1/ALK1
and sometimes MADH4/SMAD4 (Figures 2A,B) is currently
the method followed in most genetic diagnosis laboratories,
complemented with the MLPA (multiplex ligation-dependent
probe amplification) technique for large deletion/insertions of
exons. In addition, an array CNV/CGH (copy number variation/
comparative genomic hybridization) to detect even larger dupli-
cations/deletions was also proposed to complement the previous
panel (Fontalba et al., 2013).
However, ARUP Laboratories, Salt Lake City, UT, USA,
recently proposed the use of a next generation sequencing (NGS)
panel for a more efficient genetic analysis in the diagnosis of HHT
and other vascular malformations (Figure 2B; McDonald et al.,
2015). The idea is to design a panel including genes mutated
in HHT and other vascular alterations with partial phenotype/
genotype overlapping with HHT: HHT (ENG, ALK1/ACVRL1,
MADH4/SMAD4, BMP9/GDF2), pulmonary arterial hyperten-
sion (PAH) (BMPR2, CAV1, ALK1/ACVRL1), cerebral cavernous
malformation (CCM) (KRIT1, CCM1, CCM2, PDCD10), and
capillary malformation-AVM (CM-AVM) syndrome, caused by
mutations in RASA1. This way, the genetic screening includes not
only ALK1/ACVRL1 and ENG, but many more genes for almost
the same cost. Currently, this new genetics platform is under a
validation phase with clinical cases and controls. The cost of the
whole analysis using the platform is only slightly superior to the
traditional Sanger method. In summary, the design of a vascular
malformation NGS panel is clinically useful, cost-effective, and
can be updated annually to include additional vascular malfor-
mation genes, as they are identified. This approach has been
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FIGURE 2 | Sanger sequencing vs next generation sequencing (NGS).
(A) Typical chromatogram showing the results of Sanger sequencing.
(B) Sequencing scheme following capture enrichment of gene targets in a
panel of diagnosis. NGS involves three major components: sample
preparation, sequencing, and data analysis. The process begins with
extraction of genomic DNA from a patient sample. Library generation is the
process of creating random DNA fragments, of a certain size range, here
represented by 200-bp, that contain adapter sequences on both ends. This
library is the required input for most currently available NGS platforms. The
adapters are complementary to platform specific PCR and sequencing
primers. Target enrichment is achieved by RNA bait hybridization with the
specific genes of interest. Adapted from Wooderchak-Donahue et al. (2012).
recently applied to diseases affecting the joint such as aortopathies.
Thus, a direct comparison of NGS enrichment methods using an
aortopathy gene panel, show a clear improvement of the clinical
diagnostics perspective (Wooderchak-Donahue et al., 2012).
Plasma and Serum Proteins as Potential
Biomarkers of HHT: TGF-b1, VEGF, Ang-2,
and sEng
Altered levels of several plasma/serum proteins in HHT patients
and HHT animal models have been reported. Among these
proteins are transforming growth factor b1 (TGF-b1), vascular
endothelial growth factor (VEGF), angiopoietin 2 (Ang-2), and
soluble endoglin (sEng), all involved in vascular biology, including
angiogenesis and vascular remodeling (Figure 3).
Transforming Growth Factor b1
There are different genes mutated in HHT, ENG,ACVRL1,GDF2/
BMP9, and MADH4 whose proteins are involved in the TGF-
b superfamily signaling pathway of vascular endothelial cells
(Bernabeu et al., 2010). Based on this link several groups have
measured the levels of TGF-b1 in HHT patients, as the prototypic
member of the TGF-b family.
Thus, Sadick et al. (2005) reported increased plasma concen-
trations of TGF-b1 in German HHT patients with respect to
the control population (50 ng/mL vs 6 ng/mL, respectively). By
contrast, Letarte et al. (2005) found lower plasma levels of TGF-b1
in the Canadian HHT population compared to the control popu-
lation (33 ng/mL vs 44 ng/mL, respectively;Figure 3A).Moreover,
no differences in plasma TGF-b1 and -b2 levels of Chinese HHT2
FIGURE 3 | Circulating protein biomarkers in HHT. (A) The levels of
TGF-b1 secreted (over 7 h) by 15 different HUVEC with HHT1 were
significantly different (*p < 0.05) from the control HUVEC (C) tested in the
same experiment. (B) VEGF plasma concentration levels in 25 healthy
controls and 18 HHT patients. The mean values and the standard deviation
are given for each group (*p < 0.001). (C) Plasma levels of Ang-2 and (D)
plasma levels of sEng in healthy donors (n = 38), patients with HHT1 (n = 32)
and patients with HHT2 (n = 30). Significant differences between groups
(**p < 0.01) are shown. Adapted from Letarte et al. (2005) (A), Sadick et al.
(2005) (B), and Ojeda-Fernandez et al. (2010) (C,D).
patients were observed, compared to those of normal subjects
(Zhang et al., 2004; Peng et al., 2006). The reasons for these
discrepancies may be found in the different genetic background
of the human populations involved. While the first study did not
discriminate between HHT1 and HHT2 patients, Letarte et al.
(2005) showed that HHT1 patients had the lowest levels of TGF-
b1 (average 25.5 ng/mL), whereas the HHT2 population had a
mean value not significantly different from control population
(40 ng/mL in HHT2 vs 44 ng/mL). Because the German HHT
population analyzed was predominantly HHT2 (Sadick et al.,
2009) compared to the Canadian one, with more HHT1 patients
present in the study, the differences in TGF-b1 levels may reflect
geographical differences in the predominantHHT subtype of pop-
ulations (Shovlin, 2010). These data and the marked differences
in TGF-b1 levels detected in the control population (6 ng/mL vs
44 ng/mL) suggest a variety of factors which may influence an
accurate measurement of TGF-b1, including sample collection,
plasma vs serum, discrimination between latent and active forms
of TGF-b, release of TGF-b1 from platelets, clinical heterogeneity,
or lack of the standardized methodologies, leading to a limited
interpretation of the results and currently argue against TGF-b1
levels as being a good biomarker of HHT.
TGF-b1 levels are subject to variability depending on the
genetic background and may be reduced especially in HHT
patients with higher penetrance of symptoms. Indeed, Bourdeau
et al. (2001) showed that TGF-b1 circulating levels change sig-
nificantly depending on the mouse strain. Thus, TGF-b1 was
significantly lower in 129/Ola than in C57BL/6 strain. Inter-
estingly, disease prevalence in endoglin heterozygous mice is
much higher in 129/Ola (72%) than in C57BL/6 animals (7%)
(Bourdeau et al., 1999). These data suggest that modifier genes
regulatingTGF-b1 expression act in combinationwithHHTgenes
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in the development of the HHT phenotype. Thus, the levels
of TGF-b1 may be variable and correlate with the severity of
symptoms in HHT patients, depending on genetic modifiers.
Therefore, TGF-b1 levels should not be considered as a real HHT
biomarker, but rather a severity marker in the HHT genetic
background.
Vascular Endothelial Growth Factor
Previous studies have proposed that haploinsufficiency of HHT
genes impairs the TGF-b1 signaling pathway, leading to abnor-
mal vascular remodeling and angiogenesis where factors, such
as VEGF or Ang-2, play a potential role in HHT angiodysplasia
(Bernabeu et al., 2010). VEGF, also known as vascular permeabil-
ity factor, is a cytokine that induces proliferation andmigration of
endothelial cells to form new vessels and increases vascular per-
meability. Interestingly, anti-VEGF therapy has recently shown
beneficial results in HHT patients (Dupuis-Girod et al., 2012).
These benefits showed that systemic treatment with bevacizumab
is promising only in symptomatic patients with organ involvement
and life-threatening conditions (Kanellopoulou andAlexopoulou,
2013).
Early observations by Cirulli et al. (2003) indicated increased
concentration of VEGF in the serum of HHT patients compared
to control subjects (196.3 pg/mL vs 152.0 pg/mL, respectively),
proposing VEGF as a possible diagnostic marker for HHT screen-
ing. These results were later confirmed by Sadick et al. (2005) who
showed that plasma VEGF levels are 10-fold higher on average
in a group of 31 HHT patients than in a comparable number
of non-HHT population (331 pg/mL vs 20 pg/mL, respectively;
Figure 3B). Similarly, significantly higher levels of VEGF were
found in affected HHT2 family members as compared to normal
and unaffected relatives (Peng et al., 2006). In summary, VEGF
levels are increased in HHT patients compared to the control
population. There is no difference in plasma (or tissue) VEGF
levels between HHT1 and HHT2 patients (Sadick et al., 2008).
These results suggest that continuous VEGF hyper-stimulation
may lead to the development of abnormal micro-vessels due to
unbalanced angiogenesis, as seen in HHT patients. In spite of
the fact that the angiogenic factor VEGF is a putative player in
the pathogenesis of HHT, it cannot serve as a specific diagnostic
marker to discriminate between HHT1 and HHT2. Nonetheless,
because most of these studies were carried out in adults, the
existence of different VEGF levels between HHT1 and HHT2 in
children cannot be excluded.
Higher levels of VEGF in plasma were shown to be related
to higher epistaxis or gastric bleeding in a study by Giordano
et al. (2009), and recently with a few cases in our laboratory
(unpublished results). If these observations were confirmed in
future studies and plasma VEGF levels were shown to be related
to disease severity, one would not expect high VEGF levels in
children, who generally exhibit sporadic or little bleeding. The
role of VEGF in the generation of AVMs is inferred by the induc-
tion of abnormal microvasculature in the endoglin heterozygous
mouse brain, after overexpression ofVEGF (Xu et al., 2004). These
findings may stress the importance of knowing VEGF levels,
before starting an anti-angiogenic treatment in HHT population,
specially, when using Avastin (anti-VEGF antibodies).
Angiopoietin-2
Angiopoietin-2 was considered as anHHTmarker, following gene
expression studies of microarrays (Fernandez-L et al., 2007a). In
fact, Ang-2 was identified as a down-regulated gene in endothelial
cells from HHT patients. Ang-2 is a family member of vascular
growth factors, including angiopoietin-1 (Ang-1), that plays a
role in embryonic and postnatal angiogenesis. Ang-1 is criti-
cal for vessel maturation, whereas Ang-2 works as an antago-
nist of Ang-1 and promotes vessel regression in the absence of
VEGF. Thus, Ang-2 synergizes with VEGF to increase prolifer-
ation and migration of endothelial cells (Eklund and Saharinen,
2013).
Ojeda-Fernandez et al. (2010), quantified by enzyme-linked
immunosorbent assay (ELISA) the levels of Ang-2 in plasma
from HHT patients and controls. Levels of Ang-2 were reduced
in HHT (HHT1, n = 32; and HHT2, n = 30) patients com-
pared to the control population (n = 38; Figure 3C). How-
ever, some quantitative differences between the two main HHT
types were observed. While there were no significant differ-
ences between HHT1 and healthy donors, significant differences
between HHT2 and healthy subjects or HHT1 patients, were
found.
Surface and Soluble Endoglin
Analysis of endoglin surface protein levels in affected patients
strongly supports haploinsufficiency as the underlying cause
of HHT1. A comprehensive review by Abdalla and Letarte
(2006), on HHT1 samples analyzed over 10 years showed that
endoglin levels on activated monocytes and endothelial cells
[human umbilical vein endothelial cells (HUVECs)] of individ-
uals with ENG mutations are reduced almost to 50% (Pece-
Barbara et al., 1999; Abdalla and Letarte, 2006). Similarly, most
ACVRL1/ALK1 mutations lead to unstable and non-functional
mutant proteins, supporting haploinsufficiency as the predomi-
nant model of HHT2 (Abdalla et al., 2000; Abdalla and Letarte,
2006). In HHT1, as recapitulated by Abdalla and Letarte (2006),
the measure of decreased endoglin protein levels on the sur-
face of macrophages and endothelial cells, is a good marker for
HHT1. Furthermore, a decreased expression of endoglin and
ALK1 on activated monocytes and blood outgrowth endothelial
cells (BOECs) from HHT patients has been described (Sanz-
Rodriguez et al., 2004; Fernandez-L et al., 2007a), as discussed
below.
On the other hand, sEng has been associated with several
cardiovascular pathologies such as preeclampsia, acute myocar-
dial infarction, and tumor development (Li et al., 2000; Taka-
hashi et al., 2001; Venkatesha et al., 2006; Cruz-Gonzalez et al.,
2008; Hawinkels et al., 2010; Valbuena-Diez et al., 2012). Upreg-
ulated sEng levels are linked to poor cancer prognosis and cor-
relate with metastases in patients with breast cancer. Further-
more, sEng levels in the sera of pregnant women increase and
become strongly elevated, if women are developing preeclampsia,
a pregnancy-specific hypertensive syndrome (Venkatesha et al.,
2006). This soluble protein is thought to be generated by pro-
teolytic cleavage of the membrane anchored endoglin, a TGF-b
auxiliary receptor involved in angiogenesis and vascular remod-
eling and development (Hawinkels et al., 2010; Valbuena-Diez
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et al., 2012). Thus, sEng levels in HHT1 patients are expected
to be lower compared with those of control subjects because
HHT1 results from endoglin haploinsufficiency (Abdalla and
Letarte, 2006). Moreover, endoglin deficiency is detected, to a
lesser extent, in macrophages and BOECs from HHT2 patients
(Sanz-Rodriguez et al., 2004; Fernandez-L et al., 2006). In HHT1,
endoglin expression on the cell surface is reduced by approx-
imately 50% (Sanz-Rodriguez et al., 2004; Fernandez-L et al.,
2007a) while membrane endoglin levels in HHT2 range from
90 to 25%, depending on the type of ACVRL1/ALK1 mutation,
the age of the patient, and the disease severity (Fernandez-L
et al., 2006, 2007a). These studies prompted Ojeda-Fernandez
et al. (2010) to quantify by ELISA the levels of sEng, in 32
HHT1, 30 HHT2, and 38 control donors (Figure 3D). The lev-
els of soluble endoglin were significantly different in the three
groups, suggesting that sEng could be a biomarker not only
for the HHT condition, but also to distinguish between HHT1
and HHT2. Based on the results of this study, a protocol for
diagnosis was proposed combining the Ang-2 and sEng levels
in a discriminant function analysis. Reference levels for Ang-2
and sEng indicative of HHT diagnosis with 95% cut-off values
were: (i) non-HHT: sEng > 3.66 ng/mL and Ang2 > 2179.17
pg/mL; (ii) HHT1: sEng < 1.71 ng/mL, regardless Ang2 lev-
els; and (iii) HHT2: sEng > 3.19 ng/mL and Ang2 < 1128.17
pg/mL.
In summary, down-regulated protein levels of Ang-2 and sol-
uble endoglin in plasma represent potential HHT biomarkers in
the biochemical diagnosis of HHT facilitating the rapid identifi-
cation of suspected HHT patients. However, before using Ang-2
and sEng as a diagnostic test, specificity and sensitivity must be
determined in large groups of patients.
Prothrombotic Factors in HHT
HHT causes chronic nasal and gastrointestinal hemorrhage and
prothrombotic agents are commonly used for severe hemorrhage.
The use of antifibrinolytic agents, such as "-aminocaproic or
tranexamic acids, systemically administered using oral adminis-
tration show satisfactory results with an improvement in epistaxis
and the associated anemia (Fernandez-L et al., 2007b; Shovlin,
2010). However, the thrombotic risks of these drugs have not
been well defined in HHT and they are contraindicated in those
patients prone to thrombosis. For this reason, the screening for
levels of coagulant factors VIII and V and von Willebrand fac-
tor in HHT has been proposed (Shovlin et al., 2007). These
biomarkers of a prothrombotic state may be very useful before
starting an antifibrinolytic treatment in HHT patients. In order
to identify prothrombotic variables in HHT patients, and assess
their potential functional significance, a pilot ELISA-based study
comparing plasma proteins in healthy individuals with HHT
to age/sex-matched non-HHT controls was validated in a full
study of 309 consecutive HHT patients (Shovlin et al., 2007). In
the pilot study, factor VIII and von Willebrand factor antigen
concentrations were elevated in the HHT group compared to
non-HHT controls. Therefore, the increased levels of factor VIII
and other prothrombotic factors may influence thrombotic risk
in HHT. These results suggest that in HHT patients prone to
hypercoagulability, the therapies to avoid bleeding may lead to
FIGURE 4 | miRNAs as HHT biomarkers in plasma. Levels of (A) miR-27a
and (B) miR-205 were measured in plasma samples of a total of 24 HHT
patients HHT1 (n = 11) and HHT2 (n = 13) and in 16 healthy controls by
qRT-PCR. Data are expressed as relative miRNA levels normalized to two
spikes-in C. elegans miRNAs and are expressed as mean  SEM. *p < 0.05
vs healthy patients. Adapted from Tabruyn et al. (2013).
the risk of suffering deep venous thromboembolism. Accordingly,
the measurement of these prothrombotic biomarkers may con-
tribute to an individualized risk-benefit consideration and may
be helpful in HHT management (Shovlin et al., 2007; Shovlin,
2010).
MicroRNAs and Long Non-Coding RNAs
as Biomarkers for HHT
MicroRNAs are short (22 nucleotides long), non-coding RNAs
that post-transcriptionally repress gene expression by targeting
the 30-untranslated regions (30-UTR) of specific mRNAs (Bar-
tel, 2009). Some miRNAs play a major role in vascular biology
(Yang et al., 2005; Zampetaki and Mayr, 2012; Sayed et al., 2014)
and the existence of the so-called “angio-miRs” (miRNAs that
stimulate or repress angiogenesis) have opened up a novel aspect
for therapeutics associated with deregulated angiogenesis and
vascular diseases (Kane et al., 2014). Recently, the detection of
specific miRNAs in plasma has emerged as a promising diagnostic
tool and investigations are currently under development in many
diseases.
Recently, Tabruyn et al. (2013) have demonstrated a circulating
miRNA signature that could help to identify HHT patients. In
this work, 24 HHT patients (11 HHT1 and 13 HHT2) and 16
healthy controls were included. While the levels of miR-27a were
significantly higher in HHT patients than in controls, miR-205
was significantly downregulated in plasma from HHT patients
(Figure 4). The miR-27 had been previously described as a pro-
angiogenicmicro-RNA (Zhou et al., 2011), but the role ofmiR-205
in endothelial cells was unknown. In this work, miR-205 was
shown to reduce endothelial cell proliferation, migration, and
tube formation. In addition, the authors showed that the expres-
sion of miR-205 modulates the TGF-b1 pathway, by targeting
Smad1 and Smad4. It can be speculated that the combination
of miR-205 and miR-27a could be potentially used in future
to follow disease evolution, as well as to design antiangiogenic
therapies based on restoring the normal levels of these altered
miRs.
Zhang et al. (2013), in an independent study, reported the
relationship between the miR-210 and the presence of pulmonary
AVMs (PAVMs). These AVMs are present in 30–50% of patients
with HHT and can lead to bleeding, stroke, and other compli-
cations. A total of eight circulating miRNAs were found altered
Frontiers in Genetics | www.frontiersin.org March 2015 | Volume 6 | Article 1155
Botella et al. HHT biomarkers
in HHT patients with PAVMs. Among them, real-time RT-PCR
showed that the levels of circulating miR-210 were significantly
elevated in HHT patients with PAVMs, but remained unchanged
in patients without PAVMs. Interestingly, miR-210 has been
shown to be overexpressed under hypoxic conditions (Valera
et al., 2011) and is present in sporadic renal carcinoma, and von
Hippel–Lindau (VHL) dependent carcinoma (Wang et al., 2014).
Therefore, the presence of increased miR-210 levels could be
related to hypoxemia caused by the PAVMs. Further investigations
in large patient groups and sensitivity studies are needed before
circulating miR-210 could be considered as a biomarker for the
screening of clinically significant PAVMs in patients diagnosed
with HHT.
Torring et al. (2014) have recently described the first study
to assess the regulatory effects of long non-coding RNAs (lncR-
NAs) in HHT affected tissue. lncRNAs are non-protein cod-
ing transcripts longer than 200 nucleotides that are involved
in transcriptional, post-transcriptional and epigenetic regulation
(Bonasio and Shiekhattar, 2014). Using microarray technology,
Torring et al. (2014) identified lncRNAs that are differentially
expressed inHHT telangiectasial tissue comparedwithHHTnon-
telangiectasial nasal tissue. Analysis of the lncRNA transcriptome
link to biology using the GREAT software revealed several gene
ontology processes to be affected, including blood vessel mor-
phogenesis, blood vessel development, and vasculogenesis. Of
note, a central group of telangiectasial genes dysregulated in HHT
appears to be cis-regulated by differentially expressed lncRNAs.
This group of genes primarily includes CAV1, CCM2, FOXF1,
FZD4, PRSS23, RASA1, SMO, TIPARP, ZFPM2, and ZMIZ1.
Mutations in some of these genes are known to cause vascular
malformations, as in HHT. For example, mutations in CCM2
cause cerebral cavernousmalformation type 2, whereas mutations
in RASA1 lead to CM-AVM syndrome.
Mid-infrared Spectroscopy and Artificial Neural
Network Patterns to Discriminate HHT Patients
from Non-HHT Donors
A completely different approach to establish an HHT signa-
ture, was carried out by Lux et al. (2013), based on infrared
(IR) spectroscopy. IR-spectroscopy of body fluids like blood
plasma, serum, or urine has revealed disease-specific changes
in spectral signatures, for example, in diabetes mellitus (Petrich
et al., 2000), b-thalassemia (Liu et al., 2003), myocardial infarc-
tion, and heart failure (Haas et al., 2010). Interestingly, this
IR method is not measuring changes of single proteins, but
encompasses the overall metabolic changes caused by the dis-
ease, translated into specific “IR-spectra.” In the paper of Lux
et al. (2013), the subject of analysis was the “metabolic change
pattern” derived from peripheral blood plasma. IR-spectra were
obtained by Fourier-transform mid-IR spectroscopy from blood
plasma of 192 HHT patients and 191 healthy donors. Spectral
data were mathematically processed and subsequently classi-
fied and analyzed by artificial neural network (ANN) methods
and by visual analysis of scatter plots of the dominant princi-
pal components. The analyses showed that for HHT, a disease
specific IR-spectrum exists, and is significantly different from
that of the control group. According to the authors, with this
method, HHT can be diagnosed with a sensitivity and specificity
of 95%.
Data Mining for Novel HHT Biomarkers
Any biological parameter related with a disease state may be
considered a biomarker. In this sense, even differential patterns
of maturation and circulation of bone marrow cell precursors
can be associated with HHT. Recently, Massa et al. (2015), have
published that in HHT patients, the population of blood cir-
culating CD34+ endothelial cells is increased, irrespective of
the disease variant (HHT1 or HHT2). In patients with an ENG
mutation, the frequency of the cell subsets inversely correlated
with the age of the patients at time of sampling (CD34+), dis-
ease duration (CD34+, VEGFR-2+), and age at disease onset
(CD34+, CD133+, VEGFR-2 ). Moreover, Zucco et al. (2014)
reported that the percentage of CD34+ cells in peripheral blood
mononuclear cells from HHT patients was significantly higher
than in controls. Interestingly, the CD34+ cell subset has been
involved in the repair of damaged vessels (Yoder, 2012) and its
increased numbers could give some hints regarding the severity
of the vascular lesions in HHT. It will be interesting to inves-
tigate whether other the blood cell subsets are also altered in
HHT.
HHT biomarkers are expected to be the consequence of the
deregulated expression of HHT genes. Within the last years, sev-
eral omics analysis from either over- or under-expressed endoglin
or ALK1 cellular systems have led to considerable information
related to the target genes/proteins modulated by these HHT
genes. Among them: expression microarrays of the downstream
target genes affected by haploinsufficiency in endoglin or ALK1
in HHT human endothelial cells from patients. These studies
identified 168 genes downregulated, and only, 40 upregulated
genes. Differentially expressed genes are involved in migration,
angiogenesis, cell guidance, cytoskeleton organization, intercellu-
lar connections, cell proliferation, or nitric oxide (NO) synthesis
(Fernandez-L et al., 2007a).
Anothermicroarray studywas performedwith endothelial cells
from HHT and control umbilical cords (Thomas et al., 2007).
Results revealed that HHT endothelial cells had differentially
expressed genes associated with the angiogenesis activation phase,
cell guidance, intercellular connections, and with the TGF-b sig-
naling pathway.
Lux et al. (2006), using a different approach, infected a human
microvascular cell line with a recombinant constitutively active
ALK1 adenovirus and studied gene expression. Gene array analy-
sis identified 49 genes to be regulated by ALK1 signaling, includ-
ing at least 14 genes involved in angiogenesis.
Recently, expression microarrays and proteomic analysis of
human monocytic cells constitutively overexpressing endoglin
has shown hundreds of deregulated proteins involved in cellular
activities affected during aging, as well as essential biological
functions, mainly those related to cellular movement, including
cell adhesion and transmigration (Aristorena et al., 2014; Blanco
et al., 2015) These transcriptome- and proteome-wide studies
have only scratched the surface of the great deal of HHT related
gene/protein data. Hopefully, the published and upcoming data
obtained from all these experiments may constitute a valuable
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source of information that could be used in the future to identify
novel HHT biomarkers.
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